Processa pharmaceuticals cleared by fda to proceed with phase 2a trial for the treatment of gastroparesis

Hanover, md, oct. 12, 2021 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa), (“processa” or the “company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that they have been cleared by the u.s. food and drug administration (fda) to proceed with a phase 2a clinical trial of pcs12852 in patients with moderate to severe gastroparesis, an unmet medical need condition for which patients need alternative, safer treatment options.
PCSA Ratings Summary
PCSA Quant Ranking